Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

Authors:
  • LCLaure Campillo-Gimenez
    Laure Campillo-Gimenez
  • LALambert Assoumou
    Lambert Assoumou
  • MVMarc-Antoine Valantin
    Marc-Antoine Valantin
  • PPPriyadharshini Pajanirassa
    Priyadharshini Pajanirassa
  • JVJuliette Villemonteix
    Juliette Villemonteix
  • CSCathia Soulié
    Cathia Soulié
  • JCJacqueline Capeau
    Jacqueline Capeau
  • BABrigitte Autran
    Brigitte Autran
  • CKChristine Katlama
    Christine Katlama
  • AGAmélie Guihot
    Amélie Guihot

Abstract
Immunovirological consequences of a switch to a maraviroc/raltegravir dual therapy were analyzed in 16 HIV-infected patients with persistent viral load below 50 copies/ml. At 26-week postswitch, the CD4+/CD8+ ratio decreased and the CD8+ T-cell activation increased. A decrease in classical monocytes was associated with a shift toward a proinflammatory monocyte profile and negatively correlated with ultrasensitive viral load. Thus, this therapeutic switch induced a proinflammatory profile probably driven by a slight loss of virus control.

This publication has 24 references indexed in Scilit: